Research graph
References from CPX-351 plus gemtuzumab ozogamicin in relapsed or refractory acute myeloid leukemia and high-risk myelodysplastic syndrome. Local targets link to admitted publications; unresolved targets remain external evidence.
Outcomes and genetic dynamics of acute myeloid leukemia at first relapse
10.3324/haematol.2024.285057 · 2024 · External reference
Therapeutic horizon of acute myeloid leukemia: success, optimism, and challenges
10.1002/cncr.35806 · 2025 · External reference
CPX-351 (cytarabine and daunorubicin) liposome for injection versus conventional cytarabine plus daunorubicin in older patients with newly diagnosed secondary acute myeloid leukemia
10.1200/jco.2017.77.6112 · 2018 · External reference
Addition of gemtuzumab ozogamicin to induction chemotherapy in adult patients with acute myeloid leukaemia: a meta-analysis of individual patient data from randomised controlled trials
10.1016/s1470-2045(14)70281-5 · 2014 · External reference
Identification of patients with acute myeloblastic leukemia who benefit from the addition of gemtuzumab ozogamicin: results of the MRC AML15 trial
10.1200/jco.2010.31.4310 · 2011 · External reference
10.1002/ajh.26700
10.1002/ajh.26700 · 2022 · External reference
Fludarabine, cytarabine, granulocyte colony-stimulating factor, and idarubicin with gemtuzumab ozogamicin improves event-free survival in younger patients with newly diagnosed AML and overall survival in patients with NPM1 and FLT3 Mutations
10.1200/jco.23.00943 · 2024 · External reference
CPX-351 vs daunorubicin, cytarabine, and gemtuzumab ozogamicin in older adults with non–adverse-risk AML: the NCRI AML18 trial
10.1182/blood.2025031006 · 2026 · External reference
Durable remissions with Ivosidenib in IDH1-mutated relapsed or refractory AML
10.1056/nejmoa1716984 · 2018 · External reference
Gilteritinib or chemotherapy for relapsed or refractory FLT3-mutated AML
10.1056/nejmoa1902688 · 2019 · External reference
Menin inhibition with revumenib for KMT2A-rearranged relapsed or refractory acute leukemia (AUGMENT-101)
10.1200/jco.24.00826 · 2025 · External reference
Ziftomenib in relapsed or refractory NPM1-mutated AML
10.1200/jco-25-01694 · 2025 · External reference
Olutasidenib for mutated IDH1 acute myeloid leukemia: final five-year results from the phase 2 pivotal cohort
10.1186/s13045-025-01751-w · 2025 · External reference
FDA approval summary: mylotarg for treatment of patients with relapsed or Refractory CD33-positive acute myeloid leukemia
10.1634/theoncologist.2017-0604 · 2018 · External reference
Outcomes of hypomethylating agent failure in patients with myelodysplastic syndromes
10.1182/blood-2025-2075 · 2025 · External reference
Revised recommendations of the International Working Group for diagnosis, standardization of response criteria, treatment outcomes, and reporting standards for therapeutic trials in acute myeloid leukemia
10.1200/jco.2003.04.036 · 2003 · External reference
Clinical application and proposal for modification of the International Working Group (IWG) response criteria in myelodysplasia
10.1182/blood-2005-10-4149 · 2006 · External reference
Pivekimab sunirine (IMGN632), a novel CD123-targeting antibody–drug conjugate, in relapsed or refractory acute myeloid leukaemia: a phase 1/2 study
10.1016/s1470-2045(23)00674-5 · 2024 · External reference
CAR-NK cell therapy in acute myeloid leukemia: safer, smarter, and moving toward clinical translation
10.1016/j.bict.2025.100030 · 2026 · External reference
A phase 2 trial of CPX-351 combined with venetoclax in relapsed or refractory acute myeloid leukemia
10.1002/ajh.27723 · 2025 · External reference
Outcomes of patients with treated secondary acute myeloid leukemia: a high-risk subtype that warrants an independent prognostic designation
10.1002/ajh.27561 · 2025 · External reference
CPX-351 plus gemtuzumab ozogamicin for relapsed/refractory acute myelogenous leukemia: a University of California hematologic malignancies consortium trial
10.1080/10428194.2024.2438809 · 2025 · External reference
A phase I/II trial of CPX-351 + palbociclib in patients with acute myeloid leukemia
10.1182/blood-2020-139494 · 2020 · External reference
A two-part study evaluating the combination of tazemetostat and CPX-351 (Part 1) and palbociclib with CPX-351 (part 2) for the treatment of relapsed or refractory acute myeloid leukemia
10.1182/blood-2023-186671 · 2023 · External reference
CPX-351 versus 7+3 cytarabine and daunorubicin chemotherapy in older adults with newly diagnosed high-risk or secondary acute myeloid leukaemia: 5-year results of a randomised, open-label, multicentre, phase 3 trial
10.1016/s2352-3026(21)00134-4 · 2021 · External reference
CPX-351 selectively benefits patients with AML and myelodysplasia-related mutations in the pivotal randomized trial
10.1182/bloodadvances.2025019378 · 2026 · External reference
A randomized comparison of CPX-351 and FLAG-Ida in adverse karyotype AML and high-risk MDS: the UK NCRI AML19 trial
10.1182/bloodadvances.2023010276 · 2023 · External reference
A phase 2 study of ATRA, arsenic trioxide, and gemtuzumab ozogamicin in patients with high-risk APL (SWOG 0535)
10.1182/bloodadvances.2019001278 · 2020 · External reference
Long-term follow-up of a phase 2 study of all-trans retinoic acid, arsenic trioxide, and gemtuzumab ozogamicin in acute promyelocytic leukemia
10.1002/cncr.35662 · 2025 · External reference
Integrated analysis of genomics, molecular responses and outcomes of CBF-AML with FLAG based therapy on a phase 2 trial
10.1158/2643-3230.bcd-25-0477 · 2026 · External reference
